Burn, Edward http://orcid.org/0000-0002-9286-1128
Li, Xintong http://orcid.org/0000-0002-6872-5804
Delmestri, Antonella http://orcid.org/0000-0003-0388-3403
Jones, Nathan
Duarte-Salles, Talita http://orcid.org/0000-0002-8274-0357
Reyes, Carlen
Martinez-Hernandez, Eugenia http://orcid.org/0000-0002-8317-7068
Marti, Edelmira http://orcid.org/0000-0002-5678-2916
Verhamme, Katia M. C.
Rijnbeek, Peter R. http://orcid.org/0000-0003-0621-1979
Strauss, Victoria Y.
Prieto-Alhambra, Daniel http://orcid.org/0000-0002-3950-6346
Funding for this research was provided by:
European Medicines Agency in the form of a competitive tender
Article History
Received: 20 August 2021
Accepted: 1 November 2022
First Online: 23 November 2022
Competing interests
: D.P.A.’s research group has received research grants from the European Medicines Agency, from the Innovative Medicines Initiative, from Amgen, Chiesi, and from UCB Biopharma; and consultancy or speaker fees from Astellas, Amgen and UCB Biopharma. The remaining authors declare no competing interests.